Screener
Mirum Pharmaceuticals, Inc. MIRM Business Segments
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Product sales, net by Product | ||||||
| Bile Acid Medicines | $47.52M+19.9% | $46.08M+20.1% | $42.55M+20.4% | $40.78M+30.8% | $39.63M+29.8% | |
| Livmarli | $128.72M+46.0% | $113.8M+55.4% | $106.39M+66.0% | $92.24M+56.0% | $88.16M+86.7% |
FAQ
- How does Mirum Pharmaceuticals, Inc. break its business down?
- Mirum Pharmaceuticals, Inc. (MIRM) reports product sales, net by product across 2 parts — Bile Acid Medicines and Livmarli. Each is extracted from the segment footnotes and tracked over time.
- Where does Mirum Pharmaceuticals, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Mirum Pharmaceuticals, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
